News | PET Imaging | June 14, 2016

Competition Seeks First PET Tracer for Key Parkinson's Protein

First team to develop viable tracer will receive $2 million prize from The Michael J. Fox Foundation

Michael J. Fox Foundation, MJFF, Parkinson's, PET tracer, competition, SNMMI 2016

June 14, 2016 — The Michael J. Fox Foundation (MJFF) announced a $2 million prize for development of a positron emission tomography (PET) tracer to visualize the protein alpha-synuclein, the priority therapeutic target and biomarker candidate of Parkinson's disease research. The prize aims to motivate the field toward this vital research tool, which would allow for earlier and more precise diagnosis, progression tracking, and more efficient and effective intervention testing.

"The ability to image alpha-synuclein in the brain would be a game-changer for Parkinson's translational research and would rapidly accelerate testing of therapies to slow or stop disease progression," said Jamie Eberling, Ph.D., MJFF director of research programs, who announced the prize at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.

Academic and industry researchers, MJFF-funded or not, are eligible to apply for the prize. Contestants must provide pre-clinical and clinical data showing selectivity and viability of their alpha-synuclein radiotracer. Importantly, contestants must also agree to make their radiotracer available for use by the Foundation and MJFF awardees through a nonexclusive license or other MJFF-approved mechanism. There is no deadline for submission; the prize will go to the first team that shows compelling evidence.

Alpha-synuclein accumulates in the brains of people with Parkinson's disease, and researchers believe that aggregation is the cause of cell degeneration and death responsible for Parkinson's symptoms and progression. Five therapies that aim to prevent or degrade alpha-synuclein aggregates (called Lewy bodies) are currently in clinical trials, with more poised to enter human testing in the next few years.

However, the lack of an objective biological measure (or biomarker) of Parkinson's slows testing of new treatments. The ability to visualize alpha-synuclein in the brain would allow scientists to confirm diagnosis earlier, and thereby intervene earlier; monitor disease progression; and determine a patient's response to treatment in clinical studies.

MJFF is partnering Prothena Corp. plc, a biotechnology company developing protein immunotherapies for diseases including Parkinson’s, to support complementary work measuring alpha-synuclein in peripheral tissues and fluids.

The Michael J. Fox Foundation has long supported the pursuit of an alpha-synuclein PET tracer — in addition to funding of alpha-synuclein therapies and projects investigating peripheral measures of this key protein. In 2011, with little activity in the field, MJFF established a public-private Alpha-synuclein Imaging Consortium to begin work toward such a tool. If the Foundation consortium is the first to build compelling evidence of a viable, selective tracer, members of the team excluding MJFF staff will be awarded the prize. The Foundation also funds a number of independent studies toward an alpha-synuclein radiotracer.

For more information: www.michaeljfox.org

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages